Pharma — India Trademark Cases
245 decisions indexed
Page 8 of 9 · 245 total
Usv Limited v.Systopic Laboratories Limited
Usv Limited filed a suit for passing off against Systopic Laboratories Limited, alleging that the latter was deceptively using similar trade marks ('PIO-15'/'PIO-30') for medicinal preparations. The court examined issues of jurisdiction and whether the defendant's use caused confusion or deception.
Sanat Products Ltd. v.Glade Drugs And Nutraceuticals Pvt.
The Delhi High Court granted an interlocutory injunction in a passing off suit concerning pharmaceutical preparations. The plaintiff, Sanat Products Ltd., argued that the defendant's use of the mark 'REFORM' was deceptively and phonetically similar to its established trademark 'REFIRM', leading to potential confusion among consumers and medical practitioners. The court found that the similarity was likely to cause deception, especially given the nature of prescription drugs, and ruled that the balance of convenience favored granting the injunction to prevent irreparable harm to the plaintiff.
Sysmed Laboratories Pvt. Ltd. v.Panbross Pharmaceuticals
The Orissa High Court upheld a temporary injunction granted against Panbross Pharmaceuticals, finding that their product 'HYCAL FORTE' was deceptively similar to Sysmed Laboratories' established drug 'HICAL'. The court emphasized the high risk of consumer confusion in the pharmaceutical sector, where such errors can have disastrous health consequences. Given the phonetic and visual similarity between the marks, the High Court ruled that a prima facie case for passing off existed, thus dismissing the appeal.
Glaxo Group Ltd. v.Paun And Paum Chemicals
The Delhi High Court ruled in favor of Glaxo Group Ltd., finding that the defendant was infringing its trademarks 'Ostocalcium' and 'Ostocalcium Vet,' as well as engaging in passing off. The court found that the defendant's use of 'Oscal-Vet, D3' and the deceptively similar color scheme and get-up of its packaging material were likely to confuse the public. Consequently, a permanent injunction was granted, along with orders for the delivery up of infringing materials and rendition of accounts.
Usv Limited v.Systopic Laboratories Limited And Anr.
Usv Limited sought an injunction against Systopic Laboratories Limited for using trademarks (PIO, PIO-15, PIO-30) deemed deceptively similar to its own (PIOZ-15, PIOZ-30). The Madras High Court ultimately dismissed the application. The court held that the word 'PIO' is publici juris, meaning it describes the chemical ingredient and cannot be monopolized by a single party. Furthermore, the applicant failed to obtain leave to sue the first respondent and was found to have deliberately provided a false address for service, undermining its claim.
East African (I) Remedies Pvt. Ltd. v.Wallace Pharmaceuticals Ltd. And Anr.
The Delhi High Court dismissed the plaintiff's application seeking an ad interim injunction against trademark infringement. The court found that the plaintiff failed to establish a strong prima facie case, noting low historical sales figures and lack of evidence regarding goodwill. Conversely, the defendant demonstrated bona fide use, prior searches, and significant market presence with their product 'REVOX'. Consequently, the balance of convenience favored the defendant, who was allowed to continue manufacturing while being directed to deposit security for the plaintiff's interest.
Exphar Sa And Ors. v.Bharat Shah And Anr.
This appeal involved disputes concerning the trademark MALOXINE and associated copyright in its carton design. The plaintiffs, a Belgian-based company, sought permanent prohibitory injunctions against the defendants for passing off and infringement. However, the Delhi High Court ultimately ruled that it lacked the necessary territorial jurisdiction to entertain the suit or grant an interim injunction, as the plaintiff did not reside or carry on business within India.
Ipca Laboratories Ltd. v.Savita Pharmaceuticals Pvt. Ltd.
The Plaintiff filed a suit seeking to restrain the Defendant from infringing its copyright in cartons/labels and passing off goods under the trade mark 'APPETONE'. The dispute centered on whether the Plaintiff, as a prior user, was entitled to relief despite the Defendant manufacturing similar products. The court dismissed the Notice of Motion.
Khandelwal Laboratories Ltd. v.Fdc Limited
The Delhi High Court vacated an ex-parte injunction restraining the defendant from using the trade mark ZIFI, which was claimed to be deceptively similar to the plaintiff's CEFI. The court found that despite phonetic similarity, the defendant had a family of 'Z' trademarks and strong arguments regarding the weakness of pharmaceutical salt-derived marks. Considering the balance of convenience, the court ruled in favor of the defendant, allowing them to continue using their mark.
Cadila Healthcare Ltd. v.Swiss Pharma Pvt. Ltd. And Anr.
Cadila Healthcare Ltd. filed a suit alleging that Swiss Pharma Pvt. Ltd. was passing off its medicine SUPERDAC as Cadila's product SPARDAC due to deceptive similarity in the names. The trial court dismissed the suit, finding no evidence of deception or confusion. The Gujarat High Court upheld this decision, concluding that the two brand names were not deceptively similar.
Cadila Healthcare Ltd. v.Swiss Pharma Pvt. Ltd.
Cadila Healthcare Ltd. filed a suit alleging that Swiss Pharma Pvt. Ltd. was passing off its medicine, SUPERDAC, as Cadila's product, SPARDAC, due to deceptive similarity in the trade marks. The trial court dismissed the suit, finding no evidence of deception or confusion. The Gujarat High Court upheld this decision, concluding that the two names were not deceptively similar and there was no likelihood of consumer confusion.
Dr. Reddy's Laboratories Limited v.Manu Kosuri And Anr.
Dr. Reddy's Laboratories successfully sued defendants for cybersquatting and trademark infringement related to the domain name 'drreddyslab.com'. The court ruled that a domain name functions similarly to a trademark on the internet, granting it equal protection against passing off. Given the high similarity between the marks, the court found there was a clear likelihood of confusion among consumers. Consequently, the defendants were permanently restrained from using the infringing domain and were ordered to transfer 'drreddyslab.com' to Dr. Reddy's.
Wockherdt Ltd. v.Collector Of Central Excise
Wockherdt Ltd. appealed against an order classifying their product, Mannitol Injection B.P. 20% W/V, as a patent or proprietary medicine based on the design of its label. The company argued that simple labeling features like bars and color schemes do not automatically confer proprietary status unless they are registered trademarks or establish exclusive rights. The Tribunal sided with the appellant.
Mahesh Jayalal Dadhia & Another v.M/S. Thio Pharma & Others
The plaintiffs, members of the Dadhia family, sought an injunction restraining the defendants from manufacturing or trading pharmaceutical products bearing specific trademarks (BROSMIN, ACTIZYME, etc.). The dispute centered on ownership rights following a family arrangement and subsequent agreements regarding the joint business. The court found no merit in the Notice of Motion seeking injunction.
Ciba-Geigy Ltd. v.Torrent Laboratories Ltd.
The Gujarat High Court addressed an opposition filed by Ciba-Geigy against Torrent Laboratories' trademark application for 'ULCIBAN.' The court ultimately ruled in favor of Torrent, finding that despite the inclusion of 'CIBA' within 'ULCIBAN,' there was no likelihood of confusion or deception among consumers. The judgment emphasized that when assessing similarity, the mark must be viewed as a whole, and phonetic/ocular resemblance is not automatically established simply because part of the word matches.
Indo-Pharma Pharmaceutical Works Ltd. v.Citadel Fine Pharmaceuticals Ltd.
The Madras High Court dismissed the appeal filed by Indo-Pharma Pharmaceutical Works Ltd. against Citadel Fine Pharmaceuticals Ltd., upholding the lower court's refusal to grant an interim injunction. The court found that despite both parties operating in the pharmaceutical sector, their products (allopathic syrup vs. Ayurvedic capsules) were distinct in form and character. Crucially, the court held that the prefix 'ENERJ' is a common, descriptive abbreviation of 'energy,' which cannot be monopolized as a trademark, while the suffixes 'JEX' and 'JASE' are phonetically and visually dissimilar enough to prevent consumer confusion.
Torrent Pharmaceuticals Ltd. v.Union Of India (Uoi) And Ors.
Torrent Pharmaceuticals Ltd. appealed against the summary dismissal of its petition challenging the Registrar's action regarding a notice of opposition filed by Welcome Foundation Ltd. The core dispute revolved around whether the statutory provisions governing the submission of evidence during trademark opposition proceedings were mandatory or directory.
T.T.K. Pharma Limited v.Ag. Robapharam
The respondent claimed ownership of the registered trademark "Ossopan" and filed a suit for injunction against the appellant/defendant. During the pendency of the suit, the respondent sought to amend the plaint to correct an apparent mistake regarding the description of specified goods, which was inconsistent with the registration certificate. The High Court upheld the amendment, rejecting the appeal filed by the defendant.
Win-Medicare Limited v.Somacare Laboratories
The plaintiff, Win-Medicare Limited, filed an application for temporary injunction alleging that the defendant was manufacturing and marketing a similar pharmaceutical product under the deceptively similar trade mark DICMOL. The court examined the priority of adoption and use, finding prima facie evidence in favor of the plaintiff.
Collector Of Central Excise v.Raspha Labs
The Collector of Central Excise appealed against an order stating that the words 'RL' on medicine labels did not constitute a registered trade mark, but rather served as a house mark. The Tribunal examined precedents and concluded that 'RL' was only used to project the manufacturer's image generally, thus it was merely a house mark and not proprietary in nature.
M/S. Astra Pharmaceuticals (P) Ltd. v.Collector Of Central Excise, Chandigarh
The appeal challenged the classification of pharmacopoeial Dextrose injections as patent or proprietary medicines attracting central excise duty under Tariff Item 14E. The department argued that the use of a monogram ('AP ASTRA') established a connection between the manufacturer and the medicine. The Supreme Court ruled that since the mark only identified the manufacturer, it did not establish a proprietary relationship with the specific medicine.
M/S. Kamath Atul & Co. v.M/S. Cadila Laboratories (P) Ltd.
The plaintiff, M/s. Kamath Atul & Co., filed a passing off action against the defendant, M/s. Cadila Laboratories (P) Ltd., alleging that the latter was marketing an Ayurvedic herbal skin ointment under the name 'HERBINOL', which infringed upon the plaintiff's established trade mark 'HURBINOL'. The High Court dismissed the appeal but modified the temporary injunction order to restrict the defendants from marketing their product in five specific states until the suit's disposal.
Antox India (P) Ltd. v.State Drug Controller, Tamil Nadu And ...
Antox India (P) Ltd., holding a valid license for Cal-De-Ce, challenged the manufacturing license issued by the State Drug Controller, Tamil Nadu, to another party. The petitioner argued that allowing multiple manufacturers under the same trade name violates public interest and provisions of the Drugs & Cosmetics Act, 1940. The court agreed, quashing the impugned order and directing the cancellation of the second respondent's license.
Collector Of C. Ex. v.Bengal Chemicals And Pharmaceuticals
The dispute concerned whether medicines manufactured by Bengal Chemicals And Pharmaceuticals, which bore the registered trade mark 'Bengal Chemicals' on their caps, should be classified as 'Patent or Proprietary Medicines' under the Central Excises and Salt Act, 1944. The Tribunal held that merely having a registered trademark is not sufficient; the mark must indicate a proprietary interest in the medicine, especially when the medicines are already specified in pharmacopoeia.
Progro Pharmaceuticals (P) Ltd. v.Deputy Registrar Of Trade Marks, Madras
Progro Pharmaceuticals filed a writ petition challenging the rejection of its counter-statement against an opposition to the trade mark 'Helmizol'. The rejection was based on the argument that S. 21(2) is mandatory and does not allow for discretion to condone the one-month delay. The court ruled in favor of the petitioner, holding that where no outer limit is prescribed under S. 21(2), the Registrar can extend time under S. 101(l).
Union Of India v.Indo-French Pharmaceutical Company
The Union of India appealed against an order allowing Indo-French Pharmaceutical Company to clear three Indian Pharmacopoeia products without paying excise duty. The dispute centered on whether a small symbol and name used on the product label qualified as a proprietary mark under the Central Excises and Salt Act, thereby attracting excise duty.
Hoechst Pharmaceuticals Ltd. v.C.V.S. Mani
This case challenged specific amendments made to the Drugs and Cosmetics Rules, 1945, which mandated that certain single-ingredient drugs could only be marketed under their generic or proper scientific name. Petitioners, including Hoechst Pharmaceuticals, argued that this prohibition on using established trade names violated their constitutional rights. The Delhi High Court ultimately struck down the most restrictive clause of the amendment, holding it illegal and ultra vires, while allowing a lesser restriction requiring the proper name to be displayed more prominently than the trade name.
Dolphin Laboratories Pvt. Ltd. v.Kaptab Pharmaceuticals
The plaintiff (Dolphin Laboratories) sued the defendant (Kaptab Pharmaceuticals) alleging infringement/passing off regarding the trade mark 'Amotid' for the drug Amoxycilin Tri-hydrale. The core legal controversy was whether the plaintiff, in its Section 120 suit, could restrain the defendant from filing a separate passing off suit. The court held that while the defendant must stop making unjustified threats, it retains the fundamental right to institute a passing off suit.
Registrar Of Trade Marks v.Hamdard National Foundation (India)
The Delhi High Court dismissed an appeal by the Registrar of Trade Marks, upholding the single judge's decision to register the trademark 'SAFI' for medicinal preparations. The core issue was whether 'SAFI,' a word meaning 'pure' or 'clear,' was descriptive and thus unregistrable under Section 9 of the Act. The court ruled that even if a mark has an initial reference to quality, it can acquire a secondary meaning through continuous use in trade, making it capable of distinguishing the goods of a particular trader.
The Anglo French Drug Co., (Eastern) v.R.D. Tinaikar
This appeal challenged the decision of the Deputy Registrar of Trade Marks who held that a Registered Trade Marks Agent was entitled to be heard during opposition proceedings for trade mark registration. The petitioners argued that an agent could only 'act,' but not 'plead' before the Registrar, citing provisions of the Bombay Pleaders Act. The High Court dismissed the appeal, affirming the Deputy Registrar's finding.
Facing a trademark dispute?
Arctic's TM litigation team handles ~120 trademark matters per year across India, EU, and UK. From oppositions to infringement actions, we build winning arguments from precedent.